Victoria Soldatenkova

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah, Jürgen Wolf, Bhavana Konda et al. · The Lancet Oncology · 2022 · 384 citations · Full text

Thyroid Tumours, Medicine, Metronomic Therapy +9

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Thomas Brodowicz, Maciej Krzakowski, Matjaž Zwitter et al. · Lung Cancer · 2006 · 322 citations

Medicine, Cancer Management, Phase Iii Trial +6

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

William D. Tap, Andrew J. Wagner, Patrick Schöffski et al. · JAMA · 2020 · 288 citations · Full text

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion–Positive NSCLC

Caicun Zhou, Benjamin Solomon, Herbert H. Loong et al. · New England Journal of Medicine · 2023 · 186 citations · Full text

Selpercatinib in Patients With <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Alexander Drilon, Vivek Subbiah, Oliver Gautschi et al. · Journal of Clinical Oncology · 2022 · 185 citations · Full text